Michael J. Mertz

Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO.

Sequoia Vaccines, Inc. is a clinical stage pharmaceutical company engages in developing vaccine to prevent recurrent urinary tract infections and small molecules treating cancers and bacterial infections. The company was founded by Gary Eldridge in 2012 and is headquartered in St. Louis, MO.

Sequoia Vaccines, Inc. is a clinical stage pharmaceutical company engages in developing vaccine to prevent recurrent urinary tract infections and small molecules treating cancers and bacterial infections. The company was founded by Gary Eldridge in 2012 and is headquartered in St. Louis, MO.

Sequoia Vaccines, Inc. is a clinical stage pharmaceutical company engages in developing vaccine to prevent recurrent urinary tract infections and small molecules treating cancers and bacterial infections. The company was founded by Gary Eldridge in 2012 and is headquartered in St. Louis, MO.

Sequoia Vaccines, Inc. is a clinical stage pharmaceutical company engages in developing vaccine to prevent recurrent urinary tract infections and small molecules treating cancers and bacterial infections. The company was founded by Gary Eldridge in 2012 and is headquartered in St. Louis, MO.

Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO.

Sequoia Vaccines, Inc. is a clinical stage pharmaceutical company engages in developing vaccine to prevent recurrent urinary tract infections and small molecules treating cancers and bacterial infections. The company was founded by Gary Eldridge in 2012 and is headquartered in St. Louis, MO.

Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO.

Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO.

Sequoia Vaccines, Inc. is a clinical stage pharmaceutical company engages in developing vaccine to prevent recurrent urinary tract infections and small molecules treating cancers and bacterial infections. The company was founded by Gary Eldridge in 2012 and is headquartered in St. Louis, MO.